[Intraperitoneal chemo-hyperthermia with mitomycin C. Development and in vivo study of tolerability in dogs].
Peritoneal carcinosis is relatively frequent in the clinical course of digestive cancers (48% in cases with invasion of the serous membrane). Despite various therapeutic strategies, prognosis is almost always unfavourable, survival after 6 months is extremely rare. Because of the known in vitro anti-tumour effect of hyperthermia and its chemosensitizing effect during Mitomycine C therapy, we decided to develop a technique based on these two anticancer effects: intraperitoneal hyperthermia and intraperitoneal chemotherapy. Termed CHIP, or chemo-hyperthermia intraperitoneal, this new method could be used for the treatment of peritoneal carcinosis. We report here results of the necessary animal experimentation before such a method could be proposed for human anticancer therapy.
Gilly
F N
FN
Service de Chirurgie, Centre hospitalier Lyon Sud.
Carry
P Y
PY
Sayag
A C
AC
Panteix
G
G
Brachet
A
A
Salle
B
B
Baulieux
J
J
Peix
J L
JL
Braillon
G
G
D000818:Animals; D003131:Combined Modality Therapy; D013505:Digestive System Surgical Procedures; D004285:Dogs; D006979:Hyperthermia, Induced; D008099:Liver / Q000473:pathology; D016685:Mitomycin / Q000627:therapeutic use*; D010537:Peritoneum / Q000473:pathology; D011184:Postoperative Period
D016685:Mitomycin
Chimio-hyperthermie intra-péritonéale (CHIP) avec mitomycine C (MMC). Mise au point et étude in vivo de la tolérance chez le chien.